Antitumour effect of a synthetic analogue of @entity19525 on @entity19 XXXX .

@entity353 @entity10822 @entity19 @entity5 @entity294 @entity1358 @entity19525 @entity3 @entity703
OBJECTIVE: To evaluate the antitumour effect of an angio-inhibitory drug, a synthetic analogue of @entity19525 ( @entity10822 ), on @entity19 @entity703 ( @entity703 ) in vivo and in vitro. MATERIALS AND METHODS: The effect of @entity10822 on the growth of @entity703 cells in vitro was measured by angiogenesis assay and cell counting with dye exclusion. In the angiogenesis assay, @entity703 cells were injected intradermally and the number of blood vessels orientated towards the @entity5 was counted 3 days after @entity5 inoculation. To examine the effect of @entity10822 on the subcutaneous @entity5 growth and lung @entity3 of @entity703 , @entity703 cells were injected subcutaneously or intravenously in BALB/c @entity19 and they were treated with a subcutaneous injection every 3 days. RESULTS: Dose-dependent growth inhibition in vitro was observed with 50% inhibition occurring at 600 ng/ml. Angiogenesis assay revealed that administration of @entity10822 inhibited the angiogenesis induced by @entity703 in a dose-dependent manner. In the subcutaneous experiment, @entity10822 decreased the growth rate of established subcutaneous @entity5 rather than reduced the size of the @entity5 . The administration of @entity10822 in @entity19 with lung @entity3 inhibited the development of @entity3 of @entity703 without @entity353 or @entity294 . CONCLUSION: The present study demonstrated that @entity10822 had an inhibitory effect on @entity5 -induced angiogenesis and a significant anti- @entity5 effect on @entity703 . This suggests that @entity10822 could be useful in the treatment of @entity1358 . Further studies are needed to clarify whether @entity10822 is more effective when combined with other drugs such as interferons.
